Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, HOB Biotech Group's Enterprise Value is ¥5,087.5 Mil.
HOB Biotech Group's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ¥36.7 Mil. Therefore, HOB Biotech Group's EV-to-FCF for today is 138.76.
The historical rank and industry rank for HOB Biotech Group's EV-to-FCF or its related term are showing as below:
SHSE:688656'
s EV-to-FCF Range Over the Past 10 Years
Min: -10711.59 Med: -23.99 Max: 3539.11
Current: 138.76
During the past 10 years, the highest EV-to-FCF of HOB Biotech Group was 3539.11. The lowest was -10711.59. And the median was -23.99.
SHSE:688656's EV-to-FCF is ranked worse than 90.1% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.015
vs SHSE:688656: 138.76
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
HOB Biotech Group (SHSE:688656) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
HOB Biotech Group's PE Ratio (TTM) for today is calculated as:
HOB Biotech Group's share price for today is ¥79.20.
HOB Biotech Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.333.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
HOB Biotech Group EV-to-FCF Related Terms
HOB Biotech Group EV-to-FCF Historical Data
* Premium members only.
The historical data trend for HOB Biotech Group's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688656 vs ABT, SYK, MDT: EV-to-FCF Comparison
For the Medical Devices subindustry, HOB Biotech Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOB Biotech Group EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HOB Biotech Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where HOB Biotech Group's EV-to-FCF falls into.
HOB Biotech Group's current Enterprise Value is ¥5,087.5 Mil.
HOB Biotech Group's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥36.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOB Biotech Group (SHSE:688656) has a EV-to-FCF of 138.76 as of Jul. 24, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on HOB Biotech Group and its competitors. According to the industry distribution chart, HOB Biotech Group ranks #373 out of 414 companies in the Medical Devices & Instruments industry, placing it in the top 90.1%.
Is HOB Biotech Group's EV-to-FCF too high?
HOB Biotech Group's current EV-to-FCF is 138.76. The Medical Devices & Instruments industry median EV-to-FCF is 23.02. HOB Biotech Group's value of 138.76 is 502.9% above this industry median. Based on the distribution chart, HOB Biotech Group ranks #373 out of 414 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, HOB Biotech Group has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HOB Biotech Group's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HOB Biotech Group ranks #373 out of 414 companies for EV-to-FCF. This places HOB Biotech Group in the lower half of its industry. The industry median EV-to-FCF is 23.02. HOB Biotech Group's value of 138.76 is 502.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.02, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HOB Biotech Group's current EV-to-FCF of 138.76 is 502.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on HOB Biotech Group and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HOB Biotech Group's current EV-to-FCF is 138.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOB Biotech Group stock overvalued right now?
Based on GuruFocus' analysis, HOB Biotech Group (SHSE:688656) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥89.27, compared to a current price of ¥79.20 — trading 11.3% below its estimated fair value. The current EV-to-FCF is 138.76 and 502.9% above the Medical Devices & Instruments industry median of 23.02. HOB Biotech Group's overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For HOB Biotech Group (SHSE:688656), the current EV-to-FCF is 138.76 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HOB Biotech Group (SHSE:688656) Overvalued in 2026?
Based on GuruFocus' analysis, HOB Biotech Group stock appears to be undervalued.
The current stock price of ¥79.20 is trading 11.3% below its estimated GF Value™ of ¥89.27.
GuruFocus considers HOB Biotech Group to be Modestly Undervalued.
Key valuation signals for SHSE:688656:
EV-to-FCF: 138.76
GF Value™: ¥89.27 vs. price of ¥79.20 (11.3% below fair value)
Industry Position: 502.9% above the Medical Devices & Instruments median (#373 of 414)
No single metric tells the full story. See the SHSE:688656 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HOB Biotech Group Corp Ltd is an in vitro diagnostic company. The firm is specialized in providing diagnostic tools to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care.
83GF Score
Get the complete analysis for SHSE:688656
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688656 has been successfully added to your 
